Background: The 2005 outbreak of Marburg virus (MARV) infection in Angola was the most lethal MARV infection outbreak in history, with a case-fatality rate (90%) similar to that for Zaire ebolavirus (EBOV) infection. However, very little is known about the pathogenicity of MARV Angola, as few studies have been conducted to date. Therefore, the immune response was examined in MARV Angola-infected nonhuman primates.
Methods: Cynomolgus macaques were infected with MARV Angola and monitored for survival. The effect of MARV Angola on the immune system was examined by immunophenotyping whole-blood and by analyzing cytokine and chemokine levels in plasma and spleen specimens, using flow cytometry.
Results: The prominent clinical findings were rapid onset of disease and death (mean time after infection, 6.7 days), fever, depression, anorexia, petechial rash, and lymphopenia. Specifically, T, B, and natural killer cells were severely depleted in the blood by day 6. The typical cytokine storm was present, with levels of interferon γ, tumor necrosis factor, interleukin 6, and CCL2 rising in the blood early during infection.
Conclusions: MARV Angola displayed the same virulence and disease pathology as EBOV. MARV Angola appears to cause a more rapid onset and severe outcome of infection than other MARV strains.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/infdis/jiv095 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Virus Stability on Surfaces, in Bodily Fluids, in Wastewater and Different Environmental Conditions.
Methods Mol Biol
November 2024
Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
Information concerning the fundamental properties of a pathogen is essential at the beginning of an outbreak. Often, the fundamental properties of an emerging virus are unknown because the virus is new, as in the recent SARS-CoV-2 pandemic, or because the properties have not been investigated, as was the case during the West African Ebola virus epidemic and the Marburg virus epidemics in Angola and the Democratic Republic of the Congo. The amount of time that a virus can remain viable under various conditions is one of these fundamental properties.
View Article and Find Full Text PDFEvaluation of Vaccines and Therapeutics Against Marburg Virus in Nonhuman Primate Models.
Methods Mol Biol
November 2024
Galveston National Laboratory and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Marburg virus (MARV) has caused sporadic outbreaks of severe hemorrhagic fever in Africa in humans and nonhuman primates (NHPs) and has the potential to be used as a biological weapon. Currently, there are no licensed vaccines or therapeutics to respond to outbreaks or deliberate misuse. Vaccine and therapeutic efficacy testing against MARV requires animal models that accurately mimic human disease.
View Article and Find Full Text PDFEvaluating Countermeasures Against Marburg Virus Using a Mouse Model.
Methods Mol Biol
November 2024
Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.
Animal models are key tools for understanding Marburg virus (MARV) pathogenesis and evaluating novel countermeasures. Rodents, in particular, are useful model systems because they are inexpensive and easy to house and handle in maximum containment laboratories. Unfortunately, wild-type MARV, like other filoviruses, does not cause disease in immune-competent rodents and must first be adapted to the rodent host, typically through serial passaging.
View Article and Find Full Text PDFVaccine Platform Comparison: Protective Efficacy against Lethal Marburg Virus Challenge in the Hamster Model.
Int J Mol Sci
August 2024
Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.
Marburg virus (MARV), a filovirus, was first identified in 1967 in Marburg, Germany, and Belgrade, former Yugoslavia. Since then, MARV has caused sporadic outbreaks of human disease with high case fatality rates in parts of Africa, with the largest outbreak occurring in 2004/05 in Angola. From 2021 to 2023, MARV outbreaks occurred in Guinea, Ghana, New Guinea, and Tanzania, emphasizing the expansion of its endemic area into new geographical regions.
View Article and Find Full Text PDFTranscriptional profiling of immune responses in NHPs after low-dose, VSV-based vaccination against Marburg virus.
Emerg Microbes Infect
December 2023
Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
Infection with Marburg virus (MARV), the causative agent of Marburg virus disease (MVD), results in haemorrhagic disease and high case fatality rates (>40%) in humans. Despite its public health relevance, there are no licensed vaccines or therapeutics to prevent or treat MVD. A vesicular stomatitis virus (VSV)-based vaccine expressing the MARV glycoprotein (VSV-MARV) is currently in clinical development.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!